A review of new publications by the Update Committee for the American Society of Clinical Oncology found that the guidelines for the follow-up and management of patients with breast cancer who have completed treatment are still sound.
Women with primary breast cancer diagnosed at an advanced stage are at increased risk for the development of contralateral breast cancer (CBC), according to the results of a population-based study conducted in Sweden.
The FDA has approved a new ultrasound device to detect breast cancer in women with dense breasts. It will be used in conjunction with standard mammography in asymptomatic women with a negative mammogram.
In patients with heavily pretreated HER2-positive metastatic breast cancer, combination treatment with lapatinib and trastuzumab was associated with a median survival benefit of 4.5 months, according to the final results of a phase III study.